Anti‑epileptic effect of ifenprodil on neocortical pyramidal neurons in patients with malformations of cortical development

Wang,Xiongfei; He,Xun; Li,Tianfu; Shu,Yousheng; Qi,Songtao; Luan,Guoming

doi:10.3892/etm.2017.5311

Anti‑epileptic effect of ifenprodil on neocortical pyramidal neurons in patients with malformations of cortical development

Authors:
- Xiongfei Wang
- Xun He
- Tianfu Li
- Yousheng Shu
- Songtao Qi
- Guoming Luan
View Affiliations

Affiliations: Beijing Key Laboratory of Epilepsy, Department of Functional Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, P.R. China, Department of Neurology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510280, P.R. China, Beijing Key Laboratory of Epilepsy, Brain Research Institute, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, P.R. China, State Key Laboratory of Cognitive Neuroscience and Learning, IDG/McGovern Institute for Brain Research, School of Brain and Cognitive Sciences, The Collaborative Innovation Center for Brain Science, Beijing Normal University, Beijing 100875, P.R. China, Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: October 16, 2017 https://doi.org/10.3892/etm.2017.5311
Pages: 5757-5766
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ifenprodil has been demonstrated to reduce spontaneous action potentials observed by local field potential in animal models. To investigate whether ifenprodil exerts an anti‑epileptic effect on neuronal levels in humans, whole‑cell patch clamp recordings were used to study the electrophysiological membrane properties of neocortical pyramidal neurons in human brain tissues. Electrophysiological membrane properties and spontaneous spikes of neocortical pyramidal neurons were investigated by using whole‑cell patch clamp recordings, prior to and following the application of ifenprodil. In the present study, ifenprodil significantly decreased the membrane input resistance (P<0.01), membrane time constant (P<0.01), action potential amplitude (P<0.01), action potential rising rate (P<0.05) and falling rate (P<0.05) on neocortical pyramidal neurons in patients with epilepsy caused by malformations of cortical development (MCD). These results suggested that ifenprodil decreased neuronal excitability of neocortical pyramidal neurons in patients with epilepsy and MCD and demonstrated that ifenprodil may be a potentially specific treatment for refractory epilepsy caused by MCD.

View Figures

View References

1	Perucca E, French J and Bialer M: Development of new antiepileptic drugs: Challenges, incentives, and recent advances. Lancet Neurol. 6:793–804. 2007. View Article : Google Scholar : PubMed/NCBI
2	Aronica E, Becker AJ and Spreafico R: Malformations of cortical development. Brain Pathol. 22:380–401. 2012. View Article : Google Scholar : PubMed/NCBI
3	Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F and De Simoni MG: Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures. J Neurosci. 19:5054–5065. 1999.PubMed/NCBI
4	van Scheppingen J, Broekaart DW, Scholl T, Zuidberg MR, Anink JJ, Spliet WG, van Rijen PC, Czech T, Hainfellner JA, Feucht M, et al: Dysregulation of the (immuno)proteasome pathway in malformations of cortical development. J Neuroinflammation. 13:2022016. View Article : Google Scholar : PubMed/NCBI
5	Aronica E and Crino PB: Inflammation in epilepsy: Clinical observations. Epilepsia. 3 52 Suppl:S26–S32. 2011. View Article : Google Scholar
6	Zurolo E, Iyer A, Maroso M, Carbonell C, Anink JJ, Ravizza T, Fluiter K, Spliet WG, van Rijen PC, Vezzani A and Aronica E: Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain. 134:1015–1032. 2011. View Article : Google Scholar : PubMed/NCBI
7	Boer K, Jansen F, Nellist M, Redeker S, van den Ouweland AM, Spliet WG, van Nieuwenhuizen O, Troost D, Crino PB and Aronica E: Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res. 78:7–21. 2008. View Article : Google Scholar : PubMed/NCBI
8	Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, Casalgrandi M, Manfredi AA, et al: Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 16:413–419. 2010. View Article : Google Scholar : PubMed/NCBI
9	Chiavegato A, Zurolo E, Losi G, Aronica E and Carmignoto G: The inflammatory molecules IL-1β and HMGB1 can rapidly enhance focal seizure generation in a brain slice model of temporal lobe epilepsy. Front Cell Neurosci. 8:1552014. View Article : Google Scholar : PubMed/NCBI
10	Chenard BL and Menniti FS: Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des. 5:381–404. 1999.PubMed/NCBI
11	Fisher RS, Cross JH, D'Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, et al: Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 58:531–542. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hemb M, Velasco TR, Parnes MS, Wu JY, Lerner JT, Matsumoto JH, Yudovin S, Shields WD, Sankar R, Salamon N, et al: Improved outcomes in pediatric epilepsy surgery: The UCLA experience, 1986–2008. Neurology. 74:1768–1775. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hoffman WH and Haberly LB: Bursting-induced epileptiform EPSPs in slices of piriform cortex are generated by deep cells. J Neurosci. 11:2021–2031. 1991.PubMed/NCBI
14	Hoffman WH and Haberly LB: Bursting induces persistent all-or-none EPSPs by an NMDA-dependent process in piriform cortex. J Neurosci. 9:206–215. 1989.PubMed/NCBI
15	Wang B, Yin L, Zou X, Ye M, Liu Y, He T, Deng S, Jiang Y, Zheng R, Wang Y, et al: A Subtype of inhibitory interneuron with intrinsic persistent activity in human and monkey neocortex. Cell Rep. Mar 3–2015.(Epub ahead of print).
16	Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, Binaglia M, Corsini E, Di Luca M, Galli CL and Marinovich M: Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci. 23:8692–8700. 2003.PubMed/NCBI
17	Geiger JR and Jonas P: Dynamic control of presynaptic Ca(2+) inflow by fast-inactivating K(+) channels in hippocampal mossy fiber boutons. Neuron. 28:927–939. 2000. View Article : Google Scholar : PubMed/NCBI
18	Connors BW, Gutnick MJ and Prince DA: Electrophysiological properties of neocortical neurons in vitro. J Neurophysiol. 48:1302–1320. 1982.PubMed/NCBI
19	Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
20	Wang L, Zhang X, Liu L, Cui L, Yang R, Li M and Du W: Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF-kappaB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia. Brain Res. 1321:143–151. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhang R, Lao L, Ren K and Berman BM: Mechanisms of acupuncture-electroacupuncture on persistent pain. Anesthesiology. 120:482–503. 2014. View Article : Google Scholar : PubMed/NCBI
22	Bianchi ME and Manfredi AA: Immunology. Dangers in and out. Science. 323:1683–1684. 2009. View Article : Google Scholar : PubMed/NCBI
23	Bianchi ME: DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol. 81:1–5. 2007. View Article : Google Scholar : PubMed/NCBI
24	Catterall WA: Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 16:521–555. 2000. View Article : Google Scholar : PubMed/NCBI
25	Huttunen HJ and Rauvala H: Amphoterin as an extracellular regulator of cell motility: From discovery to disease. J Intern Med. 255:351–366. 2004. View Article : Google Scholar : PubMed/NCBI
26	Pedrazzi M, Patrone M, Passalacqua M, Ranzato E, Colamassaro D, Sparatore B, Pontremoli S and Melloni E: Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol. 179:8525–8532. 2007. View Article : Google Scholar : PubMed/NCBI
27	Najm IM, Ying Z, Babb T, Mohamed A, Hadam J, LaPresto E, Wyllie E, Kotagal P, Bingaman W and Foldvary N: Epileptogenicity correlated with increased N-methyl-D-aspartate receptor subunit NR2A/B in human focal cortical dysplasia. Epilepsia. 41:971–976. 2000. View Article : Google Scholar : PubMed/NCBI
28	Thomas CG, Miller AJ and Westbrook GL: Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol. 95:1727–1734. 2006. View Article : Google Scholar : PubMed/NCBI
29	Botta P, Demmou L, Kasugai Y, Markovic M, Xu C, Fadok JP, Lu T, Poe MM, Xu L, Cook JM, et al: Regulating anxiety with extrasynaptic inhibition. Nat Neurosci. 18:1493–1500. 2015. View Article : Google Scholar : PubMed/NCBI
30	Waters J and Helmchen F: Background synaptic activity is sparse in neocortex. J Neurosci. 26:8267–8277. 2006. View Article : Google Scholar : PubMed/NCBI
31	Bean BP: The action potential in mammalian central neurons. Nat Rev Neurosci. 8:451–465. 2007. View Article : Google Scholar : PubMed/NCBI
32	Gardoni F, Boraso M, Zianni E, Corsini E, Galli CL, Cattabeni F, Marinovich M, Di Luca M and Viviani B: Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1β and NMDA stimulation. J Neuroinflammation. 8:142011. View Article : Google Scholar : PubMed/NCBI
33	García-Arnandis I, Guillén MI, Gomar F, Pelletier JP, Martel-Pelletier J and Alcaraz MJ: High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes. Arthritis Res Ther. 12:R1652010. View Article : Google Scholar : PubMed/NCBI
34	Howard P, Twycross R, Shuster J, Mihalyo M, Rémi J and Wilcock A: Anti-epileptic drugs. J Pain Symptom Manage. 42:788–804. 2011. View Article : Google Scholar : PubMed/NCBI
35	Neels HM, Sierens AC, Naelaerts K, Scharpé SL, Hatfield GM and Lambert WE: Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 42:1228–1255. 2004. View Article : Google Scholar : PubMed/NCBI
36	O'Neill LA and Bowie AG: The family of five: TIR-domain-containing adaptors in toll-like receptor signalling. Nat Rev Immunol. 7:353–364. 2007. View Article : Google Scholar : PubMed/NCBI
37	Wang CX and Shuaib A: NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord. 4:143–151. 2005. View Article : Google Scholar : PubMed/NCBI
38	Tu W, Xu X, Peng L, Zhong X, Zhang W, Soundarapandian MM, Balel C, Wang M, Jia N, Zhang W, et al: DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell. 140:222–234. 2010. View Article : Google Scholar : PubMed/NCBI
39	Perin-Dureau F, Rachline J, Neyton J and Paoletti P: Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci. 22:5955–5965. 2002.PubMed/NCBI